<DOC>
	<DOCNO>NCT00074178</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , methotrexate , cyclophosphamide , etoposide phosphate , dexamethasone , cytarabine , work different way stop cancer cell divide stop grow die . Osmotic blood-brain barrier disruption use certain drug open blood vessel around brain allow anticancer substance deliver directly brain . Giving methotrexate , cyclophosphamide , etoposide phosphate osmotic blood-brain barrier disruption plus dexamethasone cytarabine may kill cancer cell . PURPOSE : Phase II trial study effectiveness give methotrexate , cyclophosphamide , etoposide phosphate osmotic blood-brain barrier disruption plus dexamethasone cytarabine treat patient primary CNS lymphoma .</brief_summary>
	<brief_title>Methotrexate , Cyclophosphamide , Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone Cytarabine Treating Patients With Primary CNS Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine toxicity efficacy methotrexate , cyclophosphamide , etoposide phosphate administer conjunction osmotic blood-brain barrier disruption dexamethasone cytarabine patient primary CNS lymphoma . Secondary - Determine ability recruit adequate number patient study . - Compare progression-free dementia-free survival standard measure overall survival , progression-free survival , disease-free survival , complete response rate , cognitive function , quality life patient treat regimen . - Determine feasibility conduct future phase III study treatment regimen patient population . - Correlate neuropsychological outcome neuroimaging ( MRI ) outcomes patient treated regimen . OUTLINE : This multicenter study . Patients receive methotrexate ( MTX ) intra-arterially 10 minute , cyclophosphamide IV 10 minute , etoposide phosphate IV 10 minute day 1 2 conjunction osmotic blood-brain barrier disruption . Patients also receive oral dexamethasone every 6 hour day 2-15 ( follow taper ) intraventricular intrathecal cytarabine day 14 . Beginning 48 hour last dose MTX , patient receive filgrastim ( G-CSF ) * subcutaneously daily 7-10 day blood count recover . Treatment repeat every 4 week 12 course absence disease progression unacceptable toxicity . NOTE : *Alternatively , patient may receive single dose pegfilgrastim , administer 24 hour completion chemotherapy Patients intraocular lymphoma also receive MTX intravitreally twice weekly vitreous clear cell slit lamp exam weekly 1 month monthly 1 year . Quality life assess baseline , 6 month , completion treatment , every 6 month 2 year annually thereafter . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 90 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm intermediate highgrade primary CNS lymphoma brain biopsy cerebrospinal fluid vitrectomy analysis No 90 day since diagnosis No systemic lymphoma NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age 16 75 Performance status ECOG 03 OR Karnofsky 40100 % Life expectancy Not specify Hematopoietic Hematocrit least 25 % ( transfusion allow ) WBC least 2,500/mm^3 Absolute granulocyte count least 1,200/mm^3 Platelet count least 100,000/mm^3 OR least low limit normal ( transfusion independent ) Hepatic Bilirubin great 2.0 time upper limit normal Renal Creatinine clearance least 30 mL/min Cardiovascular Adequate cardiac function tolerate general anesthesia Pulmonary Adequate pulmonary function tolerate general anesthesia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study participation No uncontrolled clinically significant confound medical condition within past 30 day No know allergy study agent HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 4 week since prior chemotherapy ( 6 week nitrosoureas ) Singleagent methotrexate administer within past 14 day allow Endocrine therapy Not specify Radiotherapy No prior cranial spinal radiotherapy Surgery Prior surgery biopsy allow</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>primary central nervous system lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
</DOC>